Mercer Capital Advisers Inc. trimmed its position in Johnson & Johnson (NYSE:JNJ) by 0.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,239 shares of the company’s stock after selling 313 shares during the period. Johnson & Johnson makes up approximately 7.5% of Mercer Capital Advisers Inc.’s portfolio, making the stock its biggest position. Mercer Capital Advisers Inc.’s holdings in Johnson & Johnson were worth $9,953,000 at the end of the most recent reporting period.
Other institutional investors have also recently modified their holdings of the company. Lenox Wealth Advisors Inc. boosted its stake in Johnson & Johnson by 0.6% during the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after purchasing an additional 5 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. boosted its stake in Johnson & Johnson by 241.0% during the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,190 shares of the company’s stock valued at $149,000 after purchasing an additional 841 shares during the last quarter. Ullmann Financial Group Inc. acquired a new position in Johnson & Johnson during the 1st quarter valued at about $186,000. Taylor Wealth Management Partners boosted its stake in Johnson & Johnson by 19.8% during the 1st quarter. Taylor Wealth Management Partners now owns 1,510 shares of the company’s stock valued at $188,000 after purchasing an additional 250 shares during the last quarter. Finally, Puplava Financial Services Inc. purchased a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $202,000. 66.06% of the stock is owned by institutional investors and hedge funds.
WARNING: This story was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.chaffeybreeze.com/2017/11/12/johnson-johnson-jnj-shares-sold-by-mercer-capital-advisers-inc.html.
A number of equities analysts have recently weighed in on the company. Vetr upgraded Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 target price on the stock in a research note on Monday, October 30th. Citigroup Inc. boosted their target price on Johnson & Johnson from $140.00 to $149.00 and gave the stock a “buy” rating in a research note on Monday, October 23rd. Credit Suisse Group set a $154.00 target price on Johnson & Johnson and gave the stock an “outperform” rating in a research note on Thursday, October 19th. Jefferies Group LLC boosted their target price on Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, October 16th. Finally, Barclays PLC boosted their target price on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $143.70.
Shares of Johnson & Johnson (NYSE:JNJ) opened at $139.56 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.02 and a debt-to-equity ratio of 0.36. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $144.35. The stock has a market cap of $374,930.72, a price-to-earnings ratio of 19.55, a price-to-earnings-growth ratio of 2.84 and a beta of 0.82.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.68 earnings per share. equities research analysts forecast that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 annualized dividend and a dividend yield of 2.41%. Johnson & Johnson’s payout ratio is currently 58.33%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.